10 Best US Stocks to Invest In for Long Term

8. ServiceNow, Inc. (NYSE:NOW)

5-Year Revenue CAGR: 22.77%

Number of Hedge Fund Holders: 115

ServiceNow, Inc. (NYSE:NOW) a strong Q3 performance to reinforce the bullish case for its enterprise AI and workflow automation business. On October 28, 2026, the company reported subscription revenue of $3.99 billion, up 21% year-over-year. Total revenue rose 20.5% to $4.11 billion. Current remaining performance obligations (cRPO) reached $13.65 billion, rising 20.5%, indicating continued demand for the company’s subscription offerings. What reflects stronger momentum in AI adoption is that management also raised its full-year 2026 subscription revenue and free cash flow margin outlook and increased its 2026 AI annual contract value target to $1.7 billion.

READ ALSO: ServiceNow (NOW) Needs Stronger Cash Flow to Support Its AI Expansion.

The growth opportunity received additional support on November 5, when ServiceNow, Inc. and LTM announced an expanded partnership to accelerate enterprise-wide agentic AI adoption. LTM has already deployed 1,500 ServiceNow AI agents across its operations and the companies plan to leverage their relationship with more than 700 shared customers. This agreement could help strengthen ServiceNow, Inc.’s ability to convert AI demand into broader commercial adoption.

However, investors may also want to monitor the company’s forward commitments. ServiceNow, Inc.’s Q4 guidance points to cRPO growth of 18.5%, below the 20.5% reported in Q3. This moderation, especially if it persists, could raise questions about the pace of future growth.

7. Bloom Energy Corporation (NYSE:BE)

5-Year Revenue CAGR: 34.22%

Number of Hedge Fund Holders: 116

Bloom Energy Corporation (NYSE:BE) is strengthening its position in the growing market for AI data center power. However, the timing of large-scale deployments remains a key factor for investors to consider.

On November 5, 2026, NTT DATA announced an agreement with Bloom Energy Corporation to deploy 900 megawatts (MW) of onsite power across multiple data center projects globally. Under the agreement, NTT Global Data Centers will use Bloom Energy Corporation’s fuel cell technology as a primary power source. Initial shipments are expected to begin in 2027. The collaboration is designed to expand across NTT DATA’s global data center portfolio and potentially reach gigawatt scale. This represents a significant growth opportunity for Bloom Energy Corporation, especially as data center operators seek reliable power solutions amid expanding AI infrastructure requirements. You can also take a look at our analysis of why investors should pay attention to Bloom’s building momentum.

The announcement comes after Bloom Energy Corporation reported solid financial results for the third quarter of 2026. The company reached revenue of $1.24 billion, up 138.1% year-over-year, while gross margin increased to 33.8% from 29.2%. The company also lifted its full-year 2026 revenue guidance to a range of $4.4 billion to $4.6 billion, representing 122% year-over-year growth at the midpoint. This strengthens the bullish case by showing that growing demand is translating into substantial revenue growth and improvements in profitability for the company.

However, it is worth noting that the NTT agreement’s initial shipments are not expected until 2027. This means that the opportunity still depends on successful execution and future deployments.

6. Uber Technologies, Inc. (NYSE:UBER)

5-Year Revenue CAGR: 30.66%

Number of Hedge Fund Holders: 151

On November 4, Uber Technologies, Inc. (NYSE:UBER) reported its Q3 2026 results and delivered continued growth in trips, bookings, and profitability. However, its mobility business is facing growing operational challenges.

READ NOW: Uber (UBER) Is Betting Billions on Delivery. Can Its Cash Flow Justify the Expansion?

The company delivered its fifth consecutive quarter of 20%+ Gross Bookings growth, with Gross Bookings reaching $59.8 billion, trips grew 16% to $4.1 billion. Revenue increased 10% to $14.8 billion while adjusted EBITDA jumped 31% to $3.0 billion. Non-GAAP EPS reached $0.88, up 35% year-over-year. These results show that Uber Technologies, Inc. continues to benefit from stronger consumer engagement while translating platform growth into improved profitability.

However, the outlook highlights some headwinds. According to Reuters, higher fuel costs, driver shortages, and the Middle East conflict weighed on mobility growth. Uber Technologies, Inc. said that the conflict alone reduced Q3 Mobility Gross Bookings growth by 75 basis points. The company assumes a hit of 100 basis points in Q4 ⁠as escalations coincide with the busy holiday travel season.

Moreover, Uber Technologies, Inc.’s Q4 Non-GAAP EPS guidance of $0.95 to $0.99, which represents growth of 34% to 39%, fell short of analysts’ $1.06 estimate, according to data ​compiled by LSEG. This raises concerns about near-term earnings momentum and the costs of maintaining driver supply. However, management expects Q4 Gross Bookings growth of 18% to 22%, which points to continued platform expansion despite these pressures.

5. Eli Lilly and Company (NYSE:LLY)

5-Year Revenue CAGR: 25.51%

Number of Hedge Fund Holders: 152

Eli Lilly and Company (NYSE:LLY) delivered another strong quarter and reinforced its position in the fast growing diabetes and obesity treatment markets. On October 29, the company reported its Q3 financial results, reporting revenue of $24.4 billion, up 39% year-over-year. This growth was primarily driven by Mounjaro and Zepbound. Mounjaro revenue jumped 65% to reach $10.7 billion, while Zepbound sales surged 49% to reach $5.4 billion.

The company also lifted its full-year 2026 revenue guidance from $85 to $87 billion to $91 to $92 billion, which provides further support for the bullish thesis as it continues to benefit from demand for its leading weight-management and diabetes treatments.

However, investors may also want to take into account the pricing pressures underlying this growth. US revenue increased 34%, but realized prices fell 7%. International while international realized prices also declined 29%, mainly reflecting Mounjaro’s inclusion on China’s National Reimbursement Drug List. With revenue continuing to surge despite declining realized prices, the bigger question is whether Eli Lilly and Company can sustain its growth through higher sales volumes, as explored in our analysis of how the company grew revenue while prices fell.

Furthermore, quarterly revenue included approximately $900 million in benefits, primarily from $410 million of Jardiance milestones, with no further such milestones remaining. Eli Lilly and Company said that acquired in-process research and development (IPR&D) charges of $4.57 per share also weighed on reported earnings.

On the positive side, the company reported positive Phase 3 results for retatrutide against Ozempic 2 mg, potentially strengthening its future competitive position. While this supports the overall growth outlook, pricing pressure, earnings quality, and continued dependence on its obesity and diabetes franchises remain important factors that investors should also consider.